Get the Stockscreener App
11.71
0.30%
0.0116
Fennec Pharmaceuticals Inc stock is traded at $11.71, with a volume of 120.29K.
It is up +0.30% in the last 24 hours and up +11.95% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$11.72
Open:
$11.98
24h Volume:
120.29K
Relative Volume:
0.44
Market Cap:
$410.46M
Revenue:
$51.00M
Net Income/Loss:
$-8.73M
P/E Ratio:
-39.53
EPS:
-0.2962
Net Cash Flow:
$-7.75M
1W Performance:
+7.45%
1M Performance:
+11.95%
6M Performance:
+35.43%
1Y Performance:
+40.61%
1-Day Range:
$11.65
$12.06
1-Week Range:
$11.61
$13.25
52-Week Range:
$5.65
$13.25
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
11.71 | 410.99M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.22 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | B. Riley Securities | Buy |
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
View All
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
(FENC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership - Stock Titan
Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake - Stock Titan
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance
Fennec Pharmaceuticals Announces Q2 2026 Net Income and Revenue Growth - Kalkine Media
Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question - webull.com
Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors - Stock Titan
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
B. Riley Financial Reaffirms "Buy" Rating for Adherex Technologies (NASDAQ:FENC) - MarketBeat
Wedbush Boosts Adherex Technologies (NASDAQ:FENC) Price Target to $16.00 - MarketBeat
Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade) - Seeking Alpha
Why Fennec Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
B. Riley Adjusts Fennec Pharmaceuticals Price Target to $18 From $16, Maintains Buy Rating - marketscreener.com
Fennec Pharmaceuticals Inc FRX Earnings Beat Estimates by 248.5% - Wealth Awesome
Adherex Technologies Q2 2026 Earnings Call Transcript - MarketBeat
Fennec Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $16.17, Implies 48% Upside - TradingView
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ... - Yahoo Finance
Fennec Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adherex Technologies Q2 Earnings Call Highlights - newsbreak.com
Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings Beat - marketscreener.com
Adherex Technologies (NASDAQ:FENC) Announces Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates - Yahoo Finance
Fennec Pharmaceuticals Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Fennec Pharmaceuticals posts second quarter results and issues business update - tradersunion.com
Fennec Pharmaceuticals surges 8% on Q2 earnings, revenue beat By Investing.com - Investing.com Nigeria
Fennec Pharmaceuticals surges 8% on Q2 earnings, revenue beat - Investing.com
FENNEC PHARMACEUTICALS ($FENC) Releases Q2 2026 Earnings - Quiver Quantitative
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
FENC: Q2 2026 sales surged 78% year-over-year, with profitability and strong PEDMARKⓇ demand - TradingView
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ... By GuruFocus - Investing.com Canada
Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews
Will Fennec Pharmaceuticals Inc (FRX) Beat Estimates Again in Its Next Earnings Report? - Wealth Awesome
Fennec Pharmaceuticals' Market Cap Up US$70m Following Year Of Insider Stock Buying - Moomoo
Fennec Pharmaceuticals (TSE:FRX) Sets New 12-Month HighShould You Buy? - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
Responsive Playbooks and the FENC Inflection - Stock Traders Daily
Adherex Technologies (FENC) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Fennec Pharmaceuticals Inc. - Menafn
Stocks in play: Fennec Pharmaceuticals Inc. - Yahoo! Finance Canada
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 - The Manila Times
FENC Q2'26 Earnings: EPS estimate is 0.02 USD - TradingView
Fennec sets Aug. 11 call to discuss second-quarter results - Stock Titan
Fennec Pharmaceuticals (FENC) Former Director Rosty Raykov Sells 10,000 Shares - GuruFocus
Fennec Pharmaceuticals (FENC) former director sells 10,000 shares under plan - Stock Titan
Fennec Pharmaceuticals (FENC) Gains 1.67% as Shares Advance to $9.75BPI Bull Confirmed - dars.gov.et
Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
FENC (NASDAQ: FENC) holder files to sell 10,000 common shares - Stock Titan
Fennec Pharmaceuticals (FENC) CMO gains 168 shares as award vests - Stock Titan
Fennec Pharmaceuticals (FENC) CEO gets 1,159-share award - Stock Titan
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):